ALT5 Sigma (ALTS) Competitors $7.21 +0.25 (+3.59%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$7.32 +0.12 (+1.60%) As of 08/14/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALTS vs. KURA, SAGE, ORKA, SLDB, SEPN, OPT, PGEN, RZLT, RAPP, and TERNShould you be buying ALT5 Sigma stock or one of its competitors? The main competitors of ALT5 Sigma include Kura Oncology (KURA), Sage Therapeutics (SAGE), Oruka Therapeutics (ORKA), Solid Biosciences (SLDB), Septerna (SEPN), Opthea (OPT), Precigen (PGEN), Rezolute (RZLT), Rapport Therapeutics (RAPP), and Terns Pharmaceuticals (TERN). These companies are all part of the "pharmaceutical products" industry. ALT5 Sigma vs. Its Competitors Kura Oncology Sage Therapeutics Oruka Therapeutics Solid Biosciences Septerna Opthea Precigen Rezolute Rapport Therapeutics Terns Pharmaceuticals Kura Oncology (NASDAQ:KURA) and ALT5 Sigma (NASDAQ:ALTS) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability. Does the media refer more to KURA or ALTS? In the previous week, Kura Oncology and Kura Oncology both had 17 articles in the media. ALT5 Sigma's average media sentiment score of 0.76 beat Kura Oncology's score of -0.10 indicating that ALT5 Sigma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral ALT5 Sigma 6 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, KURA or ALTS? Kura Oncology has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Comparatively, ALT5 Sigma has a beta of 2.17, meaning that its share price is 117% more volatile than the S&P 500. Which has stronger valuation and earnings, KURA or ALTS? ALT5 Sigma has lower revenue, but higher earnings than Kura Oncology. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKura Oncology$53.88M10.63-$173.98M-$2.26-2.92ALT5 Sigma$12.53M12.43-$6.24MN/AN/A Is KURA or ALTS more profitable? Kura Oncology has a net margin of 0.00% compared to ALT5 Sigma's net margin of -74.89%. Kura Oncology's return on equity of -52.32% beat ALT5 Sigma's return on equity.Company Net Margins Return on Equity Return on Assets Kura OncologyN/A -52.32% -29.59% ALT5 Sigma -74.89%-179.27%-16.28% Do analysts rate KURA or ALTS? Kura Oncology currently has a consensus price target of $24.10, indicating a potential upside of 265.15%. Given Kura Oncology's stronger consensus rating and higher possible upside, research analysts plainly believe Kura Oncology is more favorable than ALT5 Sigma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kura Oncology 0 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.86ALT5 Sigma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders believe in KURA or ALTS? 6.3% of ALT5 Sigma shares are held by institutional investors. 6.4% of Kura Oncology shares are held by company insiders. Comparatively, 4.9% of ALT5 Sigma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryKura Oncology beats ALT5 Sigma on 8 of the 14 factors compared between the two stocks. Get ALT5 Sigma News Delivered to You Automatically Sign up to receive the latest news and ratings for ALTS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALTS vs. The Competition Export to ExcelMetricALT5 SigmaFIN IndustryFinance SectorNASDAQ ExchangeMarket Cap$150.40M$7.84B$12.42B$9.84BDividend YieldN/A4.76%5.54%4.07%P/E RatioN/A19.3219.6925.74Price / Sales12.436.8325.79115.83Price / CashN/A21.5721.7659.48Price / Book13.114.372.296.15Net Income-$6.24M$311.03M$1.00B$265.06M7 Day Performance-19.62%2.72%1.75%2.60%1 Month Performance0.56%9.04%2.42%2.83%1 Year Performance298.34%32.98%542.40%25.58% ALT5 Sigma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALTSALT5 Sigma0.6327 of 5 stars$7.21+3.6%N/A+321.6%$150.40M$12.53M0.00170Trending NewsOptions VolumeGap UpHigh Trading VolumeKURAKura Oncology4.0102 of 5 stars$6.36+0.6%$24.50+285.2%-65.3%$547.15M$53.88M-3.03130SAGESage Therapeutics3.9248 of 5 stars$8.68flat$7.85-9.6%N/A$543.54M$41.24M-1.78690ORKAOruka Therapeutics2.964 of 5 stars$15.50+8.4%$40.38+160.5%N/A$535.40MN/A-3.44N/ANews CoverageEarnings ReportAnalyst ForecastAnalyst RevisionSLDBSolid Biosciences3.5131 of 5 stars$6.70-1.8%$15.10+125.4%-26.1%$528.66M$8.09M-2.24100News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionSEPNSepterna1.7447 of 5 stars$11.65-1.6%$26.75+129.6%N/A$527.57M$1.08M0.00N/ANews CoverageEarnings ReportUpcoming EarningsAnalyst RevisionOPTOpthea0.4012 of 5 stars$3.41+7.2%$1.33-60.9%+47.6%$524.84M$120K0.008News CoverageGap UpHigh Trading VolumePGENPrecigen4.0486 of 5 stars$1.93+9.7%$6.00+210.9%+65.2%$519.52M$3.92M-3.45190News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionRZLTRezolute3.1909 of 5 stars$5.86-0.7%$12.20+108.2%+48.5%$513.28MN/A-5.1040Positive NewsRAPPRapport Therapeutics1.7603 of 5 stars$14.43+2.8%$28.00+94.0%-26.8%$512.43MN/A-4.18N/AEarnings ReportAnalyst RevisionTERNTerns Pharmaceuticals4.0271 of 5 stars$6.08+5.7%$15.63+157.0%+4.3%$502.19MN/A-5.5840 Related Companies and Tools Related Companies KURA Alternatives SAGE Alternatives ORKA Alternatives SLDB Alternatives SEPN Alternatives OPT Alternatives PGEN Alternatives RZLT Alternatives RAPP Alternatives TERN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALTS) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALT5 Sigma Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share ALT5 Sigma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.